Cord Blood Technology

The Cord Blood Technology report provides an in-depth patent landscape analysis covering 18,232 patents filed across primary jurisdictions from 2001 to 2024. The dataset is derived from international patent filings and focuses on technological developments in cord blood collection, stem-cell preservation, cell therapy, regenerative medicine, tissue engineering, medicinal preparations, disease treatment, diagnostic methods, and biological-material analysis. By integrating quantitative patent data with descriptive statistics, artificial intelligence, natural language processing, topic modeling, clustering methods, and IPC-based technology classification, the report establishes a structured foundation for assessing patent activity, technological advancements, and development trends within cord blood technologies. This approach supports insights into competitive positioning, market coverage, and future innovation opportunities in stem-cell applications, tissue regeneration, biological preservation, therapeutic preparations, cell cultivation, and medical research.

The report is organized into key sections, each offering critical insights into various aspects of the cord blood industry. The primary sections include the Landscape Overview, Market and Competitor Analysis, Technology Analysis, and Key Players’ Patent Profiles. Each section provides a structured perspective designed to support strategic decisions related to technology development, new product development, investment, licensing, collaboration, mergers and acquisitions, and market entry.

Landscape Overview

The landscape overview presents a clear picture of patent activity in cord blood technologies, tracing trends from 2001 to 2024. The report identifies 18,232 patents, including 4,938 active patents, 6,410 pending patents, and 6,562 inactive, discontinued, or expired patents. Patent activity peaked in 2021, while 61% of all identified patents have been registered since 2014. The United States leads global patent registrations with 7,069 patents, followed by China with 2,758 patents, while Europe, South Korea, Israel, and other jurisdictions contribute at lower levels, indicating strong international engagement in cord blood innovation.

Market Analysis Section

The market analysis section explores the competitive dimensions of cord blood technologies by examining patent-market coverage, leading applicants, patent owners, highly cited organizations, collaboration networks, applicant activity, and pending patents. Anthrogenesis Corporation leads patent applications with 360 patents, followed by MiMedx Group Inc. with 279, the University of Texas with 195, and the University of California with 189. Other leading applicants include CorMatrix Cardiovascular, Celularity Inc., Ethicon Inc., Medipost Co. Ltd., TissueTech Inc., and DePuy Synthes. Celularity Inc. holds the largest patent portfolio, followed by Clarity, Anthrogenesis Corporation, and MiMedx Group Inc. Ethicon Inc. leads highly cited applicants with 3,786 citations, followed by Anthrogenesis Corporation and Moderna Therapeutics. By aligning patent activity with stem-cell banking, regenerative medicine, cell therapy, tissue engineering, medicinal products, diagnostics, and biological research, this section highlights competitive activity across biotechnology and healthcare markets.

Technology Analysis Section

In the technology analysis section, the report reviews core technological areas such as medical or veterinary science, hygiene, biochemistry, microbiology, enzymology, mutation and genetic engineering, organic chemistry, measuring and testing, physical and chemical processes, and information technology adapted for medical applications. Innovations in medicinal preparations, stem-cell cultivation, microorganism and enzyme preservation, genetic engineering, tissue maintenance, therapeutic compounds, peptides, biological-material analysis, sterilization methods, diagnostic procedures, surgical applications, and cell-based treatments are identified as important drivers of advancement in cord blood technologies.

Top Player Section

The top player section offers insights into leading organizations active in cord blood technologies, including Anthrogenesis Corporation, MiMedx Group Inc., and the University of Texas. Each player is evaluated based on patent-family activity, technological focus, collaboration, key patents, topic modeling, and patent clustering. The section also highlights broader activity by the University of California, CorMatrix Cardiovascular, Celularity Inc., Ethicon Inc., Medipost Co. Ltd., TissueTech Inc., and DePuy Synthes. Strategic focuses include stem-cell preservation, regenerative medicine, tissue repair, medicinal preparations, cell cultivation, therapeutic applications, biological materials, disease treatment, and medical-device technologies.

Overall, the report provides a comprehensive view of cord blood technologies by combining patent trends, competitive insights, technological analysis, and key-player intelligence. It serves as a resource for stakeholders involved in R&D, product development, technology strategy, market entry, stem-cell banking, regenerative medicine, cell therapy, biotechnology, tissue engineering, medical devices, diagnostics, therapeutic development, and academic research.

What You Will Get:

• 56 Pages PDF Full Report
• Detailed Patent Charts and Technology Figures
• Patent Profiles of Three Leading Players

People Who Might Be Interested in the Report:

• Chief Marketing Officer
• Business Development Professionals
• Corporate Strategy Executives
• R&D and Innovation Officers
• Investment Analysts
• Product Managers
• Marketing Directors
• Sales Directors
• Vice President - Sales
• Vice President - Marketing
• Heads of Marketing
• Analysts
• Corporate Planning Professionals
• Product Marketing Managers
• Market Intelligence Experts
• Heads of Innovation
• Strategy Heads
• Chief Operating Officers
• Business Analysts
• Sales Consultants
• Academics